AstraZeneca earns another approval in jam-packed Chinese PD-(L)1 market, this time in late-stage lung cancer
One of the first entrants in the PD-(L)1 market in China, British drugmaker AstraZeneca is now looking to cement its advantage there with another approval for checkpoint inhibitor Imfinzi.
Imfinzi was approved by China’s NMPA as a combination with platinum-based chemotherapy for first-line use in “extensive-stage” small cell lung cancer, an advanced form of the disease associated with particularly poor outcomes for patients, the drugmaker said Monday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.